Is Fertility Preservation Feasible and Safe With Neoadjuvant Therapy for Breast Cancer?
作者信息
Hershlag Avner, Mullin Christine, Bristow Sara L
机构信息
Northwell Health, Manhasset, New Hyde, NY.
Donald and Barabara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY.
出版信息
J Glob Oncol. 2018 Apr 5;4. doi: 10.1200/JGO.17.00213. eCollection 2018.
Abstract
摘要
相似文献
1
Is Fertility Preservation Feasible and Safe With Neoadjuvant Therapy for Breast Cancer?新辅助治疗乳腺癌时生育力保存是否可行且安全？
J Glob Oncol. 2018 Apr 5;4. doi: 10.1200/JGO.17.00213. eCollection 2018.
2
Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.接受新辅助治疗的II-III期乳腺癌女性患者的卵巢刺激生育力保存及治疗时机
Breast Cancer Res Treat. 2017 Aug;165(1):151-159. doi: 10.1007/s10549-017-4288-3. Epub 2017 May 13.
3
Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer.随机起始的卵巢刺激用于生育力保存似乎不太可能延迟乳腺癌新辅助化疗的开始。
Hum Reprod. 2017 Oct 1;32(10):2123-2129. doi: 10.1093/humrep/dex276.
4
Fertility preservation does not delay the initiation of chemotherapy in breast cancer patients treated with adjuvant or neo-adjuvant chemotherapy.生育力保存并不会延迟辅助或新辅助化疗乳腺癌患者的化疗起始时间。
Breast Cancer Res Treat. 2020 Nov;184(2):433-444. doi: 10.1007/s10549-020-05858-1. Epub 2020 Aug 13.
5
Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies.在乳腺癌患者体外受精的控制性卵巢刺激过程中联合使用他莫昔芬可提高生育力保留治疗策略的安全性。
Fertil Steril. 2014 Aug;102(2):488-495.e3. doi: 10.1016/j.fertnstert.2014.05.017. Epub 2014 Jun 14.
6
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center.大型综合性癌症中心乳腺癌患者生育力保存及妊娠结局的模式。
J Womens Health (Larchmt). 2019 Apr;28(4):544-550. doi: 10.1089/jwh.2018.6986. Epub 2018 Jul 2.
7
Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancer.哪些患者会选择进行生育力保存治疗？一项乳腺癌患者生育力保存预测因素的多中心分析。
Fertil Steril. 2012 Mar;97(3):671-6. doi: 10.1016/j.fertnstert.2011.12.008. Epub 2012 Jan 4.
8
The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival.生育力保存对乳腺癌治疗时机、复发和生存的影响。
Cancer. 2021 Oct 15;127(20):3872-3880. doi: 10.1002/cncr.33601. Epub 2021 Jun 23.
9
Is controlled ovarian stimulation safe in patients with hormone receptor-positive breast cancer receiving neoadjuvant chemotherapy?接受新辅助化疗的激素受体阳性乳腺癌患者行控制性卵巢刺激安全吗？
ESMO Open. 2024 Feb;9(2):102228. doi: 10.1016/j.esmoop.2023.102228. Epub 2024 Jan 16.
10
Rethinking neoadjuvant chemotherapy for breast cancer.重新思考乳腺癌的新辅助化疗
BMJ. 2018 Jan 11;360:j5913. doi: 10.1136/bmj.j5913.
引用本文的文献
1
Oncofertility as a Universal Right and a Global Oncology Priority.生育力保护作为一项普遍权利和全球肿瘤学的优先事项。
JCO Glob Oncol. 2020 Mar;6:314-316. doi: 10.1200/GO.19.00337.
本文引用的文献
1
Vitrification of embryos and oocytes for fertility preservation in cancer patients.癌症患者生育力保存中胚胎与卵母细胞的玻璃化冷冻
Reprod Med Biol. 2016 Feb 29;15(4):227-233. doi: 10.1007/s12522-016-0239-7. eCollection 2016 Oct.
2
The Role of Oncofertility Clinics in Facilitating Access to Reproductive Specialists.肿瘤生育诊所 在促进获得生殖专家服务方面的作用。
J Patient Exp. 2016 Dec;3(4):131-136. doi: 10.1177/2374373516685960. Epub 2016 Dec 1.
3
Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.接受新辅助治疗的II-III期乳腺癌女性患者的卵巢刺激生育力保存及治疗时机
Breast Cancer Res Treat. 2017 Aug;165(1):151-159. doi: 10.1007/s10549-017-4288-3. Epub 2017 May 13.
4
Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer.癌症女性为保留生育功能进行卵母细胞玻璃化冷冻及解冻后的产科结局
Reprod Biomed Online. 2014 Dec;29(6):722-8. doi: 10.1016/j.rbmo.2014.09.002. Epub 2014 Sep 10.
5
Cancer statistics, 2014.癌症统计数据，2014 年。
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.
6
Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion.面临性腺毒性治疗的患者的生育力保存和生殖：委员会意见。
Fertil Steril. 2013 Nov;100(5):1224-31. doi: 10.1016/j.fertnstert.2013.08.041. Epub 2013 Oct 2.
7
Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients.在乳腺癌患者的生育力保存中，使用来曲唑-促性腺激素方案进行连续两次卵巢刺激周期的安全性和可行性。
Fertil Steril. 2013 Dec;100(6):1681-5.e1. doi: 10.1016/j.fertnstert.2013.08.030. Epub 2013 Sep 19.
8
Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update.癌症患者的生育力保存：美国临床肿瘤学会临床实践指南更新。
J Clin Oncol. 2013 Jul 1;31(19):2500-10. doi: 10.1200/JCO.2013.49.2678. Epub 2013 May 28.
9
Fertility preservation consultation for women with cancer: are we helping patients make high-quality decisions?癌症患者的生育力保存咨询：我们是否在帮助患者做出高质量的决策？
Reprod Biomed Online. 2013 Jul;27(1):96-103. doi: 10.1016/j.rbmo.2013.03.004. Epub 2013 Mar 26.
10
Ovarian stimulation in cancer patients.卵巢刺激在癌症患者中的应用。
Fertil Steril. 2013 May;99(6):1476-84. doi: 10.1016/j.fertnstert.2013.03.029.
Zotero 插件